Skip to Main Content


Skip Nav Destination


Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading


In the Spotlight

Priority Briefs

Novel immunotherapeutic strategies are needed to reduce PDAC mortality and metastatic potential. The data suggest that EUS-RFA provides an opportunity to address PDAC chemo- and immunotherapeutic resistance by stimulating the immune system and modulating the desmoplastic stroma.

Despite the success of CD19-targeted CAR T-cell therapy, patients can still relapse due to CD19 antigen loss. The data clarify the relationship between genomic alterations and CD19 relapse and highlight a resistance mechanism to this targeted cancer immunotherapy.

Research Articles

The authors show that cDC1 facilitate CNS antitumor immunity by capturing tumor antigens and trafficking them to the dura and CNS-draining cervical lymph nodes to prime CD8+ T-cell responses. DC antigen uptake in human glioblastoma is also demonstrated.

Anti-VISTA treatment overcomes adaptive resistance to immunotherapy through reprogramming myeloid suppression and relieving T-cell quiescence, highlighting the potential therapeutic impact of mAb-targeting of the VISTA immune checkpoint in cancer.

The clinical and biological impact of ectonucleotidases CD73 and CD39 in pancreatic adenocarcinoma (PDAC) are poorly defined. The authors reveal complementary roles for CD73 and CD39 and uncover a novel mechanism whereby CD73 promotes immune escape in PDAC.

Galectin 4 is a cancer cell–produced protein abundant in pancreatic tumors. The data show that galectin 4 blocks antitumor immunity and identify galectin 4 as a potential novel drug target for treating pancreatic cancer.

The authors show that engineering the CD3 subunit to prevent membrane lipid–mediated inhibition of CD3ε cytoplasmic domain release and subsequent TCR signaling provides a strategy to functionally engineer the TCR/CD3 complex for T cell–based cancer immunotherapy.

CaMKK2 is a target being considered for anticancer therapeutic development. The authors show CaMKK2 expression preserves NK-cell fitness in the tumor microenvironment and slows the progression of metastatic tumors—findings that should be considered when applying CaMKK2-modulating therapies.

The authors show that a novel and safe AAV-based cancer vaccine incorporating TLR9 signaling inhibition and blockade of PD-1/PD-L1 checkpoints on DCs and T cells elicits high immunogenicity for tumor-specific antigens, triggering better responses to radiotherapy.

Acknowledgment to Reviewers

Close Modal

or Create an Account

Close Modal
Close Modal